Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate-Reference-Cited by-同舟云学术

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate

Published:2023-06-21 Issue:4 Volume:4 Page:
ISSN:2688-2663
Container-title:MedComm
language:en
Short-container-title:MedComm

Author:

Wu Hong¹²,Ge Juan¹³,Zou Fengming¹²,Jiang Zongru¹,Wang Beilei¹²,Yuan Xinyu¹³,Long Kaili¹³,Liu Jing¹²³,Wang Wenchao¹²³,Liu Qingsong¹²³

Affiliation:

1. Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science Chinese Academy of Sciences Hefei Anhui China

2. Hefei Cancer Hospital Chinese Academy of Sciences Hefei Anhui China

3. University of Science and Technology of China Hefei Anhui China

Publisher

Wiley

Subject

Cell Biology,Biochemistry (medical),Genetics (clinical),Computer Science Applications,Drug Discovery,Genetics,Oncology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mco2.294

Reference5 articles.

1. Targeting FLT3 mutations in AML: review of current knowledge and evidence

2. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

3. Involvement of STAT5 in Oncogenesis

4. Structural and functional consequences of the STAT5BN642H driver mutation

5. ATP Inhibits the Transcription Factor STAT5b

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling effect, combinations, and clinical applications of triciribine;Journal of Chemotherapy;2024-09-14

2. A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy;Clinical Cancer Research;2024-03-04